Neuroscience

#Antibodies #Biotechnology #Collaboration #Neurodegenerative disorders #Neuroscience

Neurodegenerative collaboration seeks novel drug candidates 

Neurimmune has signed an expanded drug discovery collaboration agreement with Ono Pharmaceutical, which is focused on creating antibody drugs against new therapeutic targets in the field of neurodegenerative diseases utilising Neurimmune’s proprietary Reverse Translational Medicine (RTM) technology platform, an antibody drug creation approach.  Background  In November 2017, Ono and Neurimmune signed… Read More

#News

#Alzheimer's #Events #Neuroscience

AlzeCure gets late-breaking neuroscience abstract accepted  

AlzeCure Pharma, a pharmaceutical company that develops small molecule candidate drugs for diseases affecting the central nervous system, has announced that an abstract on clinical data of its candidate drug ACD856 has been accepted for a poster presentation at AD/PD 2022, which this year will be held in Barcelona on… Read More

#News

#Biotechnology #Microbiome #Neuroscience

Gut-brain research could result in improved cognitive performance 

In a collaborative project funded by the Next Generation Technologies Fund, researchers from the University of Newcastle and Queensland University of Technology in Australia will investigate the human, microbial and environmental interactions that affect cognitive performance, coined the ‘cognobiome’, by analysing the gut microbiome of soldiers.  The study … Read More

#News

#Biosciences #Drug targets #Neuroscience #Schizophrenia

Collaboration to develop treatment for neuropsychiatric disorders 

Neurocrine Biosciences and Sosei Group Corporation have collaborated to develop novel muscarinic receptor agonists, which Neurocrine Biosciences intends to study in the treatment for schizophrenia, dementia and other neuropsychiatric disorders.  The agreement terms  Under the terms of the agreement, Neurocrine Biosciences gains development and commercialisation rights to… Read More

#News

Human brain
#Drug development #Drug discovery #Healthcare #Neuroscience #Pharmaceuticals

NICE approves drug which treats EDS caused by narcolepsy 

Jazz Pharmaceuticals’ Sunosi (solriamfetol) has been issued a positive Final Appraisal Document (FAD) from the National Institute for Health and Care Excellence (NICE), recommending the drug for adults with excessive daytime sleepiness (EDS) caused by narcolepsy.1  When is solriamfetol needed?  Solriamfetol is recommended as an option for treating EDS… Read More

#News #Trending News

#Imaging #Neuroscience #Neurotechnology #Technology

Inscopix showcases new brain mapping technology 

Inscopix, a brain mapping platform company developing neurotechnologies for improved disease treatments, displayed the latest product and research innovations around its miniature microscope-based neural circuitry technology at the 50th annual meeting of the Society for Neuroscience (SfN), which was held virtually November 8-11.  Showcasing new technologies that enable… Read More

#News

#Drug development #Neuroscience #Therapeutics

Appointment seeks to boost brain disorder therapy development 

Inscopix, a brain mapping platform, appointed David Gray as Chief Scientific Officer (CSO) in a new position to discover and develop more effective therapies for brain disorders.  Inscopix provides brain research tools to basic and translational researchers in academia as well as biotech and pharma companies in neuroscience. Read More

#News

#Drug discovery #Neuroscience #Psychedelics

Experienced neuroscientist joins Beckley Psytech as CMO 

Beckley Psytech, a clinical stage, biotechnology company dedicated to addressing neuropsychiatric disorders through the novel application of psychedelic medicines, has appointed Frank Wiegand as Chief Medical Officer.  Dr. Wiegand, a trained neurologist and neuroscientist, joins Beckley Psytech after more than 20 years with Janssen (a Johnson & Johnson company), where… Read More

#News

#Alzheimer's #Drug discovery #Genetics #Life sciences #Neuroscience #Therapeutics

Is new thinking the key to unlocking Alzheimer’s treatment?

Professor Paul Whiting, Chief Scientific Officer of The Alzheimer’s Research UK UCL Drug Discovery Institute (ARUK UCL DDI), and Stephane Martinez, product manager and neuroscience expert in PerkinElmer’s Life Sciences segment, share expert insights on Alzheimer’s Disease research today and where discovery and therapeutic approaches might be headed next. Read More

#Editor's Choice #News #Opinion

Human brain
#Clinical trials #Neuroscience #Pharmacokinetics / Pharmacodynamics

Patients dosed in Phase I trial assessing psychiatric disorders 

Beckley Psytech has dosed the first cohort of volunteers in a clinical trial exploring the safety of its novel formulation of intranasal 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT).  The Phase I study is designed as a double-blind, randomised, single ascending dose study to evaluate the safety and tolerability of a single intranasal dose of… Read More

#News

#Neuroscience #Pharmaceuticals

Biotech to develop treatment for neurodegenerative disease 

A team of medical and pharmaceutical experts has founded SynaptixBio, an Oxford-based research company working to develop the world’s first disease-modifying treatment for TUBB4a leukodystrophy, including H-ABC – a debilitating and potentially life-limiting condition. This is a sponsored research agreement with Children’s Hospital of Philadelphia (CHOP) in the US. Read More

#News

#Collaboration #iPSC #Neuroscience

Neuroscience collaboration expands to include novel cell type 

Evotec has expanded its collaboration with Bristol Myers Squibb to include a new cell type.  The collaboration was initiated in December 2016 with the goal of identifying disease-modifying treatments for a broad range of neurodegenerative diseases. Currently approved drugs only offer short-term management of the patients’… Read More

#News

#Biosciences #Neuroscience

Tuning in to the brain’s neural network

The brain: how much don’t we know? Dr Jim Ross, Chief Technology Officer and Co-founder of Axion BioSystems, asks and discusses the answers to this question. Epilepsy, amyotrophic lateral sclerosis (ALS), Alzheimer’s — we hear these brain disease names all the time, but it feels like we never hear about effective treatments or cures. While medical advances are gradually… Read More

#Editor's Choice #Exclusive Content #News

#Molecular Biology #Neuroscience #Pharmaceuticals

Novel analgesic drug is based on Nobel prize-winning discoveries 

AlzeCure Pharma says its novel clinical candidate drug ACD440 for peripheral neuropathic pain is based on the seminal discoveries of TRPV1 by Professor David Julius, for which he was awarded the Nobel Prize in Medicine 2021.  Julius, Professor and Chair of the Department of Physiology and Morris Herzstein Chair in Molecular Biology… Read More

#News

#Drug development #Neurodegenerative disorders #Neuroscience #Parkinson's #Pharmaceuticals

Partnership for commercialisation of Parkinson’s drug in Europe 

BIAL has entered into an agreement with Sunovion Pharmaceuticals whereby BIAL received exclusive commercial license rights to commercialise apomorphine sublingual film in the European Union (EU), the European Economic Area (EEA) and the United Kingdom.  Apomorphine sublingual film (APL-130277) is a novel thin film formulation of apomorphine that dissolves… Read More

#News

#Events #Neuroscience

Registrations open for Neuroscience 2021 

Register now for Neuroscience 2021, an SfN annual meeting where for the first time, the conference will have a hybrid format, featuring both virtual and in-person programming. A single registration fee will give attendees access to both formats.  Neuroscience 2021 will take place November 8 -11 virtually, and November… Read More

#News